Loading clinical trials...
Loading clinical trials...
Phase I Feasibility and Safety Study of Nivolumab in Combination With Irinotecan in Relapsed or Refractory Small Cell Lung Cancer (SCLC) Followed by Maintenance Nivolumab
This study will determine the frequency of adverse events (side effects) in patients with relapsed or refractory small cell lung cancer (SCLC) when given nivolumab and irinotecan together followed by nivolumab maintenance. This study will test the safety of the study treatments when given together and see what effect (good or bad) it has on participants and their cancer.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Georgia Cancer Center at AU Medical Center
Augusta, Georgia, United States
Start Date
January 6, 2020
Primary Completion Date
May 26, 2022
Completion Date
May 26, 2022
Last Updated
June 14, 2022
10
ACTUAL participants
Nivolumab 10 MG/ML Intravenous Solution [OPDIVO]
DRUG
Irinotecan Injection [Camptosar]
DRUG
Lead Sponsor
Augusta University
NCT07336732
NCT04585750
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07046923